MaxCyte, Inc.

MaxCyte, Inc. (MXCT) Market Cap

MaxCyte, Inc. has a market capitalization of $91.8M.

Financials based on reported quarter end 2025-12-31

Price: $0.86

β–Ό -0.03 (-3.53%)

Market Cap: 91.77M

NASDAQ Β· time unavailable

CEO: Maher Masoud

Sector: Healthcare

Industry: Medical - Devices

IPO Date: 2021-07-30

Website: https://maxcyte.com

MaxCyte, Inc. (MXCT) - Company Information

Market Cap: 91.77M Β· Sector: Healthcare

MaxCyte, Inc., a global life sciences company, engages in the discovery, development, and commercialization of next-generation cell therapies. Its products include ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. The company also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company was incorporated in 1998 and is headquartered in Rockville, Maryland.

Analyst Sentiment

72%
Strong Buy

Based on 6 ratings

Analyst 1Y Forecast: $0.00

Average target (based on 2 sources)

Consensus Price Target

Low

$6

Median

$6

High

$6

Average

$6

Potential Upside: 598.6%

Price & Moving Averages

Loading chart...

Fundamentals Overview

Loading fundamentals overview...

πŸ“Š AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2025-12-31

"MXCT reported revenue of $7.3M with a net loss of $9.6M and an EPS of -$0.1. The company is experiencing significant challenges, evidenced by a 1-year price decline of 76.51% and negative operating cash flow of $2.7M. While the total assets stand at $202.5M, the liabilities amount to $31.0M, leading to a positive net debt of $2.1M. The overall financial health reflects substantial losses and cash outflows, indicating potential sustainability concerns. Notably, the company has not distributed dividends and faces pressure regarding market performance. Analysts currently set a median price target of $6, which is significantly higher than the current price of $0.74, suggesting potential upside if the company addresses its operational issues and stabilizes its performance."

Revenue Growth

Neutral

Minimal revenue growth; substantial losses reported.

Profitability

Neutral

Negative net income and EPS indicate poor profitability.

Cash Flow Quality

Neutral

Operating cash flow is negative, indicating cash burn.

Leverage & Balance Sheet

Fair

Strong equity position relative to liabilities.

Shareholder Returns

Neutral

No dividends and poor stock price performance.

Analyst Sentiment & Valuation

Neutral

Analysts see potential upside, but current market performance is weak.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Management’s tone is upbeat on fundamentals and longer-term platform differentiation (ExPERT DTX traction, CASGEVY ramp, SecurDx growth). However, the Q&A pressure reveals why core revenue declines are expected to deepen in 2026: management attributes it largely to a discrete ~$4M core revenue headwind embedded in guidanceβ€”split roughly half leases lost from SPL customers that exited/terminated and half processing assemblies tied to the largest customer’s supply-chain and inventory drawdown, plus a midyear lease reduction from manufacturing footprint reoptimization. Analysts challenged whether share is being lost; management explicitly denies deterioration of fundamentals and frames upside as industry demand improving, but the company is already baking in customer-specific contraction and timing effects. The clearest operational hurdle is customer inventory/lease normalization rather than a market collapse, while milestone/royalty assumptions (haircut/timing) and SPL sign cadence (expect at least three; first potentially early/mid second half) remain key swing factors for the revenue recovery narrative.

AI IconGrowth Catalysts

  • Launch of ExPERT DTX (modular 96-well electroporation) designed to remove transfection as an experimental variable; enables workflow continuity from discovery through cGMP platforms without reoptimization
  • CASGEVY ramp (commercial royalty/usage ramp expected throughout 2026)
  • SecurDx expected year-over-year growth in 2026 as integration matures and regulatory environment favors off-target risk assessment

Business Development

  • SPL portfolio scale: 31 SPL agreements total; four new SPLs signed in 2025
  • New and later-stage clinical pipeline includes named programs expected to enter pivotal studies within 18 months: zuma-cell (CRISPR Therapeutics), Wu-CAR-T-007 (WuXi-GENE), Asia-cell (Imugene), and two undisclosed SPL partners
  • Commercial therapy supported: CASGEVY (Vertex/CRISPR ecosystem mentioned; Vertex reiterated multibillion-dollar potential)

AI IconFinancial Highlights

  • Full-year revenue: $33.0M (down from $38.6M in 2024; -15%)
  • Full-year core revenue: $29.6M (down from $32.5M; -9%)
  • Full-year SPL program-related revenue: $3.4M (down from $6.1M; -~45%)
  • Q4 2025 revenue: $7.3M (down from $8.7M; -16%)
  • Q4 core revenue: $6.8M (down from $8.6M; -22%)
  • Q4 gross margin: 78% vs 74% in Q4 2024; excluding inventory provisions and SPL program-related revenue, non-GAAP adjusted gross margin 78% vs 84%
  • Operating expenses Q4 2025: $9.0M vs $19.3M in Q4 2024; impacted by non-cash goodwill impairment of $3.6M in Q4
  • No debt; cash, cash equivalents, and investments: $155.6M at end of 2025
  • 2025 mix: SPL-derived core revenue 47% vs 55% in 2024 (reflecting program exits and reduced purchasing from largest commercial-stage partner)
  • 2026 guidance: total revenue $30M-$32M; core $25M-$27M; SPL program-related $5M
  • 2026 guidance headwinds baked in: approx. $4M core revenue headwind vs 2025 (about half Processing Assemblies, half leases)
  • 2026 guidance for SPL program-related revenue includes: ~$2M expected commercial royalty revenue and remainder milestones; mentions a seven-figure milestone received in Q1 2026

AI IconCapital Funding

  • No debt as of year-end 2025
  • Cash runway: company anticipates at least $136M in cash/cash equivalents/investments at end of 2026
  • Reduced annual cash burn by over $16M in 2025 via restructuring/cost-efficiency actions

AI IconStrategy & Ops

  • Restructured to right-size spending; company states it does not expect meaningful operating expense growth from current levels
  • Integration of acquired SecurDx into MaxCyte (2025 integration continues into 2026)
  • Cost structure: entered 2026 on a β€œdramatically different spending trajectory” vs prior operating model

AI IconMarket Outlook

  • 2026 quarterly shape: Q1 expected to be lightest quarter for core revenue; back half weighted year
  • Guidance incorporates SPL customer license termination not related to platform performance (began impacting 2025; continues into 2026)
  • SPL agreement cadence expectation: continue signing at least 3 in 2026; reaffirmed 3-5/year framing (though first signing visibility shifted to early/mid second half timing)

AI IconRisks & Headwinds

  • Largest stated hurdle: $4M core revenue headwind in 2026 relative to 2025 due to: (i) leases lost from SPL customers/program exits (about half of $4M; especially impacts first half), and (ii) processing assemblies impact from largest customer’s inventory drawdown/reorganization plus midyear reduction in leases due to manufacturing site reorganization (second half impact)
  • License termination from an SPL customer for reasons unrelated to platform performance; included in 2026 guidance
  • Program rationalization: lost six SPL clinical programs during 2025; annualized revenue from discontinued programs will not recur in 2026
  • Comparability headwind at largest customer: lease revenue has difficult year-over-year comparison due to midyear lease reduction following site reorganization; company expects stabilization during 2026
  • Non-GAAP gross margin dilution: adjusted gross margin 78% vs 84% in Q4 2024 (excluding inventory provisions and SPL program-related revenue)

Sentiment: CAUTIOUS

Note: This summary was synthesized by AI from the MXCT Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

Loading financial data and tables...
πŸ“

SEC Filings (MXCT)

Β© 2026 Stock Market Info β€” MaxCyte, Inc. (MXCT) Financial Profile